12 stories mentioning AMRXUpdated 4d ago
Every FINWIRES story that references AMRX, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Amneal Pharmaceuticals (AMRX) has an average rating of overweight and mean price target of $20.75, according to analysts polled by FactSet.
Jason B. Daly, Executive Vice President, Chief Legal Officer, on August 11, 2026, sold 216,613 shares in Amneal Pharmaceuticals (AMRX) for $3,771,050. Following the Form 4 filing with the SEC, Daly has control over a total of 35,171 Class A common shares of the company, with 35,171 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1723128/000162828026056754/xslF345X05/wk-form4_1786652494.xml
Nikita Shah, Executive Vice President, on August 12, 2026, sold 146,403 shares in Amneal Pharmaceuticals (AMRX) for $2,563,517. Following the Form 4 filing with the SEC, Shah has control over a total of 253,390 Class A common shares of the company, with 253,390 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1723128/000162828026056757/xslF345X05/wk-form4_1786652518.xml
Amneal Pharmaceuticals (AMRX) said Monday it has completed the acquisition of Kashiv BioSciences.The deal will give Amneal access to the global biosimilars market, with over $300 billion in expected biologics loss-of-exclusivity in the next decade, the company said.Price: $18.12, Change: $-0.02, Percent Change: -0.11%
Amneal Pharmaceuticals (AMRX) has a favorable setup with near-term growth from several biosimilar/generic product approvals and launches that could provide further upside, UBS said in a note Monday.The brokerage also said that the stock was weak in the last two days despite strong Q2 results and outlook, providing an attractive buying opportunity for the stock.UBS said the company, for the longer term, is focused on its biosimilar portfolio to benefit from the large wave for upcoming loss of exclusivity, with 75% targeting lower competition opportunities and 25% focused on larger markets.The brokerage also said the new product launches could add $1 billion to $2 billion of incremental revenue by 2030.UBS maintained the company's buy rating and raised the price target to $25 from $23.Price: $18.81, Change: $+0.49, Percent Change: +2.67%
UBS Adjusts Amneal Pharmaceuticals Price Target to $23 From $19, Maintains Buy Rating
Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) are among the first seven companies selected by the U.S. Food and Drug Administration for a pilot program aimed at accelerating reviews of new domestic manufacturing facilities, CNBC reported Monday, citing FDA spokesperson Benjamin Nichols.The other participants in the FDA's PreCheck pilot program are Amneal Pharmaceuticals (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, the report said.The program allows regulators to begin reviewing new manufacturing facilities while they are still under construction, which the agency estimates could save companies up to 14 months, according to the report.Eli Lilly, Regeneron and FDA did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $1228.24, Change: $+20.12, Percent Change: +1.67%
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%.The iShares Biotechnology ETF (IBB) declined 0.5%.In corporate news, Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary. Amneal Pharmaceuticals' shares rose 2.1%.
Healthcare stocks were rising premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7% and the iShares Biotechnology ETF (IBB) 0.3% higher.Amneal Pharmaceuticals (AMRX) stock was up more than 2% after the company said interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.BioCardia (BCDA) has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction, the company said. Shares of BioCardia were up more than 33% pre-bell.
Healthcare stocks were rising premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7% and the iShares Biotechnology ETF (IBB) 0.3% higher.Amneal Pharmaceuticals (AMRX) stock was up more than 1% after the company said interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.
Healthcare stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.5% higher and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Biogen (BIIB) shares were up more than 1% after the company said the US Food and Drug Administration has granted breakthrough therapy designation for Salanersen to treat spinal muscular atrophy, a rare, genetic and neuromuscular disease.Royal Philips (PHG) and WellSpan Health said they have entered into a seven-year partnership focused on research, innovation, and the deployment of advanced imaging and diagnostic technologies across WellSpan's network. Shares of Royal Philips were up more than 1% pre-bell.Amneal Pharmaceuticals (AMRX) stock was 1% higher after the company said has received the US Food and Drug Administration's approval for its romidepsin injection solution.
Amneal Pharmaceuticals (AMRX) has an average rating of buy and mean price target of $17.17, according to analysts polled by FactSet.
